middle.news
Clinuvel reveals a broader drug delivery strategy backed by A$250 million
9:59am on Friday 6th of November, 2026 AEDT
•
Biotechnology and pharmaceuticals
Read Story
Clinuvel reveals a broader drug delivery strategy backed by A$250 million
9:59am on Friday 6th of November, 2026 AEDT
Key Points
A$220 million FY2027-FY2030 spending plan, excluding capex and communications costs
A$30 million reserve for potential licensing or acquisitions
CUV107 first patient treatment delayed three months to February 2027
CUV105 topline results expected in December 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clinuvel Pharmaceuticals (ASX:CUV)
OPEN ARTICLE